[Br:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:9]2[C:10]([C:28](O)=[O:29])=[CH:11][C:12]3[N:16]([CH2:17][CH2:18][C:19](=[O:25])[N:20]4[CH2:24][CH2:23][CH2:22][CH2:21]4)[CH:15]=[N:14][C:13]=3[C:26]=2[F:27])=[C:4]([Cl:31])[CH:3]=1.Cl.[CH:33]1([CH2:36][O:37][NH2:38])[CH2:35][CH2:34]1>>[CH:33]1([CH2:36][O:37][NH:38][C:28]([C:10]2[C:9]([NH:8][C:5]3[CH:6]=[CH:7][C:2]([Br:1])=[CH:3][C:4]=3[Cl:31])=[C:26]([F:27])[C:13]3[N:14]=[CH:15][N:16]([CH2:17][CH2:18][C:19](=[O:25])[N:20]4[CH2:24][CH2:23][CH2:22][CH2:21]4)[C:12]=3[CH:11]=2)=[O:29])[CH2:35][CH2:34]1The title compound is prepared from 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-1-yl-propyl)-3H-benzoimidazole-5-carboxylic acid and O-cyclopropylmethyl-hydroxylamine hydrochloride by the standard coupling procedure described in Step A: MS APCI (+) m/z 578, 580 (M+, Br pattern) detected; 1H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 8.42 (s, 1H), 8.01 (s, 1H), 7.76 (s, 1H), 7.62 (s, 1H), 7.28 (d, 1H), 6.39 (890 m, 1H), 4.52 (t, 2H), 3.66 (d, 2H), 3.33 (t, 2H), 3.28 (t, 2H), 2.89 (t, 2H), 1.83 (m, 2H), 1.76 (m, 2H), 1.06 (m, 1H), 0.49 (m, 1H), 0.22 (m, 2H); 19F NMR (376 MHz, DMSO-d6)−132.94 (s, 1F).